fashion -WSS

fashion

author：explore 2025-10-04 06:31:52 - browse：91783

Adam's take main illustration — Molly Ferguson/STAT

The eye disease physician in charge of a committee that flagged a rare but severe side effect involving a newly approved drug from Apellis Pharmaceuticals has financial ties to a competing drugmaker. The conflict raises questions about his supervision of an emerging safety issue for patients and its impact on the financial health of Apellis.

Peter Kaiser, a retinal disease expert who runs the Cole Eye Institute at the Cleveland Clinic, failed to report consulting fees and stock ownership in Iveric Bio on a financial disclosure form maintained by the American Society of Retina Specialists, or ASRS. Iveric Bio is developing a treatment for geographic atrophy, a common, age-related cause of vision loss and the same indication for which the Apellis drug was approved.

The financial conflict, which was undisclosed until after Kaiser was contacted about it by STAT, is relevant because Kaiser also chairs a committee of the ASRS responsible for monitoring the safety of retina drugs and devices. On July 15, Kaiser’s committee sent a letter to member doctors, alerting them to reports of eye inflammation in people receiving injections of Syfovre, the treatment recently approved and launched by Apellis.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Why scientists need input from humanists on sensitive research

WSS

It's been 20 years since Dolly the sheep. Where's my clone?

Readout Newsletter: CAR

RaDonda Vaught links Vanderbilt hospital issues to patient death

CommonSpirit Health keeps growing, even as it loses money

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

FDA advisers back CAR

focus

fashion

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

EpiPen alternative approval delay highlights citizen petition issue

Virginia high school admissions case could be legal follow

Changes to biosimilar regulatory framework must prioritize patients

Dobbs anniversary: the lost opportunity of abortion as health care

Steward Health Care Massachusetts hospitals face fiscal disaster

23andMe had bad news about my health. I wish a person had delivered it

Intarcia’s device

Malaria cases in Florida and Texas: Here’s what you need to know

Intarcia’s device

leisure time

RaDonda Vaught links Vanderbilt hospital issues to patient death

Male and female sex labels in research insufficient, scientists say

CDC's new outbreak response network to include Northeastern

Thermo Fisher plant for manufacturing gene therapies to expand

As AI in medicine takes off, can 'human in the loop' prevent harm?

FDA advisers back CAR

hotspot

knowledge

Wikipedia

leisure time